Introduction
The field of radiochemistry is increasingly migrating toward the use of commercially available automated synthesis modules for production of clinical radiopharmaceutical doses. The advantages of such a strategy over more traditional 'manual' synthetic approaches are clear and include: (i) automation of radiochemical syntheses providing robust, repeatable processes; (ii) the ability to handle multiple Curies of radioactivity safely enabling positron emission tomography (PET) Centers to produce and distribute hundreds of doses daily; (iii) facilitated regulatory compliance through manufacturer IQ/OQ/PQ and scheduled maintenance protocols performed on synthesis modules by authorized personnel; and (iv) improved radiation safety through elimination of manual operations. Despite these numerous significant advantages, the move toward exclusive use of automated synthesis modules also has some associated challenges. Chief among these is the issue of re-configuring synthesis modules for production of radiopharmaceuticals that require nonconventional radiochemistry (such radiochemical strategies have been the subject of several recent major review articles [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] ) while maintaining full automation. Furthermore, what is the best method to simplify making such frequently nontrivial changes in module configuration so that multiple operators can make them with a minimal chance for error?
At the University of Michigan PET Center, fluorine-18-labeled radiopharmaceuticals (with the exception of [ 18 F]FDG) are prepared using General Electric Medical Systems (GEMS) TracerLab FX FN automated synthesis modules. As the demand for clinical doses of different fluorine-18-labeled radiopharmaceuticals, many of which are prepared using complex radiochemical techniques, continues to increase, we [11] [12] [13] and others [14] [15] [16] [17] [18] [19] [20] [21] [22] have had to address the issue of frequent synthesis module reconfiguration. For example, recently we reported reconfiguration of a TracerLab FX C-Pro to allow preparation of multiple carbon-11-labeled radiopharmaceuticals without the need to open the hot-cell door between syntheses, 12 and modifications to a TracerLab FX FN enabling production of [

General modifications to the tracerlab FX FN
The Tracerlab FX FN synthesis module is installed 'out-of-the-box' in its most basic configuration illustrated in Figure 3 . This configuration is suitable for straightforward production of radiopharmaceuticals requiring HPLC purification (e.g. FLT or FAZA, discussed in Tracerlab Production with HPLC Purification section) and can easily be reconfigured to incorporate a reformulation (e.g. for production of MPPF or FEOBV, discussed in Tracerlab Production with HPLC Purification and SPE Reformulation section and illustrated in Figure 7 ). However, with some simple modifications the TracerLab FX FN can also be used to produce radiopharmaceuticals using other strategies such as the gas phase reactions outlined elsewhere in this article.
The first modification involves the delivery line from the cyclotron target. This line was originally just pushed through a hole in the septum of the target vial. However, if this line is clipped in half and the two parts re-connected using luer lock fittings, then target delivery can easily be switched between the target vial and, for example, the round-bottomed dilution flask (necessary for production of [ 18 F]sodium fluoride as discussed in Tracerlab Production with SPE Purification section) or directly on to a QMA Sep-Pak, with minimal risk of damaging the delivery line. The latter approach of trapping a target dump directly onto a QMA Sep-Pak has been adapted by our group for straightforward and safe transportation of fluoride to satellite PET centers. The QMA SepPak is housed in a lead pig prior to fluoride-18 delivery (Figure 2) , and the luer lock fitting on the cyclotron delivery line is connected to the lines of the QMA delivery system. After fluoride delivery, the delivery line can easily be disconnected and the pig safely transferred to a DOT approved Type A container for transport.
The second modification to the Tracerlab FX FN is similar, and involves incorporating luer lock fittings into both the line connecting V-18 to the round-bottomed dilution flask and also the line connecting V-17 to the round-bottomed dilution flask. These fittings are essential for production of [ 18 as consumables and customer responsible maintenance items by GEMS, they do not invalidate the manufacturer IQ/OQ. In order to verify that the alternative synthesis module configurations are suitable, three process verification (qualification) runs are completed for each radiopharmaceutical prior to preparation of clinical doses.
General synthesis considerations
Unless otherwise stated, reagents and solvents were commercially available and used without further purification: sodium chloride, 0.9% USP and Sterile Water for Injection, USP were purchased from Hospira; ethanol was purchased from American Regent; anhydrous acetonitrile, potassium carbonate, sodium acetate, hydrochloric acid, sodium dihydrogenphosphate, dribromomethane, acetic acid, DMSO, DIPEA, tetrapropylammonium hydroxide and TSTU were purchased from Sigma Aldrich; kryptofix-2.2.2 was purchased from Acros Organics and HPLC grade acetonitrile was purchased from Fisher Scientific.
Precursors and standards were commercially available unless otherwise indicated. FLT (standard and DMT-Boc-Nosyl/cyclic precursors), MPPF (standard and precursor), fluorocholine (standard) and SFB (standard and precursor) were purchased from ABX Advanced Biochemicals. Sodium fluoride and dimethylamino ethanol (fluorocholine precursor) were purchased from Sigma Aldrich. then typically eluted into the reaction vessel using aqueous potassium carbonate (3.0-3.5 mg in 0.4-0.5 mL water). A solution of kryptofix-2.2.2 (15-20 mg in 1 mL of acetonitrile) was then added to the reaction vessel and the fluoride-18 was dried by evaporating the water-acetonitrile azeotrope. Evaporation of the azeotrope was achieved by heating the reaction vessel to 801C and drawing full vacuum for 4 min. After this time, the reaction vessel was cooled to 601C and subjected to both an argon stream and the vacuum simultaneously for an additional 4 min. 18 F]FLT in high yields (23% nondecay corrected) and eliminates purification and QC issues associated with DMT contaminants, although to the best of our knowledge this precursor is not yet commercially available. Therefore, in addition to the Boc-Boc-Nosyl method, a synthetic strategy using the standard commercially available 2,3 0 -anhydro-cyclic precursor is also reported herein.
Synthesis procedures Method A: Boc-Boc-Nosyl precursor: To prepare FLT using Method A, the Tracerlab synthesis module was used in the original 'out-of-the-box' configuration illustrated in Figure 3 and reagent vials were loaded as follows: Vial 1: potassium carbonate Following drying of the fluoride using the general procedure, Boc-Boc-Nosyl FLT precursor (17.5 mg in 1 mL MeCN) was added and the reaction vessel was heated at 1351C for 3 min. The acetonitrile reaction solvent was then evaporated and 1 M HCl (1.0 mL) was added to remove the Boc groups. The deprotection was heated at 1101C for 5 min after which time the reaction vessel was cooled to room temperature and neutralized with 2 M NaOAc (0.5 mL). The crude reaction mixture was diluted, passed through an alumina Sep-Pak to remove unreacted fluoride-18 and purified by semi-preparative HPLC (column: Phenomonex Synergi Hydro-RP, 250 Â 10 mm; mobile phase: 8% EtOH : 92% 21 mM sodium phosphate (v/v); flow rate: 5.5 mL/min). A typical trace is shown in Figure 4 . The peak corresponding to [ Method B: 2,3 0 -anhydro-cyclic precursor: To prepare FLT using Method B, the Tracerlab synthesis module was used in the original 'out-of-the-box' configuration illustrated in Figure 3 and reagent vials were loaded as follows: Vial 1: potassium carbonate (3.5 mg in 0.5 mL water); Vial 2: kryptofix-2.2.2 (15 mg in 1 mL MeCN); Vial 3: 2,3 0 -anhydro-cyclic precursor (10 mg in 1.0 mL DMSO); Vial 4: NaOH (0.25 M, 0.35 mL); Vial 5: aq. sodium dihydrogen phosphate (0.25 M, 0.75 mL); Vial 6: semi-preparative HPLC mobile phase (5% EtOH: 95% 10 mM sodium dihydrogenphosphate, 1.75 mL).
Following drying of the fluoride using the general procedure, 2,3 0 -anhydro-cyclic FLT precursor (10 mg in 1 mL DMSO) was added and the reaction vessel was heated at 1601C for 10 min. After this time the reaction was cooled to 501C and 0.25 M NaOH (0.35 mL) was added for deprotection. The deprotection was heated at 501C for 4 min after which time the reaction was neutralized with 0.25 M aq. sodium dihydrogen phosphate (0.75 mL). The crude reaction mixture was diluted with 1.75 mL of HPLC mobile phase, passed through an alumina Sep-Pak to remove unreacted fluoride-18 and purified by semi-preparative HPLC (column: Alltech Econosphere C18 10 m, 250Â 10 mm; mobile phase: 5% EtOH : 95% 10 mM sodium dihydrogenphosphate (v/v); flow rate: 5.0 mL/min). A representative HPLC trace is illustrated in Figure 5 . The peak corresponding to [ 18 F]FLT was collected into the collection vial of the TracerLab, from which it was then passed through a sterile Millipore Millex-GS filter into a sterile dose vial. Doses were released for quality control testing as described in Quality Control Procedures section, and the yield of Tumor hypoxia results when tumor cells have been deprived of oxygen, frequently occuring when a tumor has outgrown its blood supply. It is important to determine if a tumor is hypoxic as soon as possible, because such tumors are typically resistant to radiotherapy and chemotherapy and require alternative treatment strategies. 2-Nitroimidazoles are an important class of compound known to be retained in higher levels in hypoxic tumor cells than the corresponding normoxic cells. The reason for the increased uptake is that in a hypoxic environment 2-nitroimidazoles undergo intracellular reduction which leads to fragmentation into species which are unable to pass back out of the cell. An analogous process is also known to occur in myochardial ischemia. [30] [31] [32] [33] [34] [35] that are finding widespread use in diagnosis of tumor hypoxia and monitroring subsequent response to therapy.
Synthesis procedures: To prepare FAZA, the Tracerlab synthesis module was used in the original 'out-of-the-box' configuration illustrated in Figure 3 and reagent vials were loaded as follows: Vial 1: potassium carbonate (3.5 mg in 0.5 mL water); Vial 2: kryptofix-2.2.2 (15 mg in 1 mL MeCN); Vial 3: FAZA precursor (5 mg in 0.7 mL DMSO); Vial 4: NaOH (0.1 M, 1.0 mL); Vial 5: aq. sodium dihydrogen phosphate (0.25 M, 0.5 mL); Vial 6: semi-preparative HPLC mobile phase (3% EtOH : 97% 10 mM sodium dihydrogenphosphate, 1.0 mL). ]fluoride and the reaction was heated to 1001C with stirring for 10 min. After this time, the reaction was cooled to 401C and 0.1 M aqueous sodium hydroxide (1 mL) was added. The reaction was stirred for 5 min at 401C to hydrolyze the acetate protecting groups. After hydrolysis, the crude reaction mixture was diluted with 0.25 M aqueous sodium dihydrogen phosphate solution (0.5 mL) and HPLC mobile phase (1 mL). The diluted reaction mixture was passed through an alumina Sep-P ak cartridge and then purified by semi-preparative HPLC (column: Alltech Econsosphere C18 10 m, 250Â 10 mm; mobile phase: 3% ethanol: 97% 10 mM sodium dihydrogenphosphate (v/v); flow rate: 4 mL/min). The fraction corresponding to [ Figure 6 ) was collected for 1 min into a vial precharged with 0.9% sodium chloride, USP (3.8 mL) and sodium phosphates, USP (0.2 mL). The final formulation (8 mL) was then passed through a sterile filter into a sterile vial to provide [ Figure 7 , incorporating the dilution flask for the reformulation process, and reagent vials were loaded as follows: Vial 1: potassium carbonate (3.5 mg in 0.5 mL water); Vial 2: kryptofix-2.2.2 (15 mg in 1 mL MeCN); Vial 3: MPPF precursor (10 mg in 0.5 mL DMSO); Vial 6: HPLC mobile phase (3.0 mL), Vial 7: 0.9% sodium chloride for injection, USP (9.5 mL); Vial 8: ethanol (0.5 mL); Vial 9: sterile water for injection, USP (12 mL); round-bottomed flask: water (50 mL).
Following drying of the fluoride using the general procedure, MPPF precursor (10 mg in 0.5 mL DMSO) was then added and the reaction vessel was heated at 1401C for 20 min. After this time, the reaction vessel was cooled to room temperature and the crude reaction mixture was diluted, passed through an alumina Sep-Pak and purified by semi-preparative HPLC (column: Phenomonex Luna C18, 250 Â 10 mm; mobile phase: 55% 50 mM NaOAc (pH = 5) : 18% THF : 27% MeOH (v/v); flow rate: 5 mL/min). A representative HPLC trace is shown in Figure 8 . The fraction corresponding to [ 46-49 Furthermore, cholinergic function has been shown to correlate with cognitive function parameters. 50, 51 There has therefore been great interest in developing imaging agents to reliably quantify cholinergic function in vivo. One such approach targets the vesicular ACh transporter (VAChT) in cholinergic terminals with radiolabeled forms of the drug vesamicol. 52 A mounting body of evidence points to VAChT as being a very specific marker of cholinergic terminals, spurring a search for suitable radioligands for measuring VAChT in vivo. With this goal in mind, we have studied a class of analogs called benzovesamicols, discovered by Rogers et al., 53 and identified a number of novel radiolabeled benzovesamicol analogs which distribute in vivo in patterns that correlate closely with the densities of marker proteins of the cholinergic nerve terminal. 54 Analogs with radioiodine, carbon-11, or fluorine-18 labels at the 5 position of the 2-hydroxy-3-N-(4-phenyl)-piperidino-tetralin frame-work, which we term 5-substituted-benzovesamicols, have shown particularly favorable imaging properties. Figure 7 , incorporating the dilution flask for the reformulation process, and reagent vials were loaded as follows: Vial 1: potassium carbonate (3.5 mg in 0.5 mL water); Vial 2: kryptofix-2.2.2 (15 mg in 1 mL MeCN); Vial 3: FEOBV precursor (0.2-0.5 mg in 0.5 mL DMSO); Vial 6: sterile water (2.0 mL)/acetonitrile (1.5 mL); Vial 7: 0.9% sodium chloride for injection, USP (9.5 mL); Vial 8: ethanol (0.5 mL); Vial 9: sterile water for injection, USP (10 mL); round-bottomed dilution flask: sterile water (40 mL).
Following drying of the fluoride using the general procedure FEOBV precursor (0.2-0.5 mg) dissolved in anhydrous DMSO (0.5 mL) was then added to the reactor vessel. The reaction mixture was then heated at 1201C for 10 min and then cooled to 501C. The resulting mixture was diluted with 3.5 mL of an aqueous acetonitrile solution. The diluted reaction mixture was passed through a Sep-Pak Light Alumina-N, and loaded onto a semi-preparative HPLC (column: Phenomenex Synergi Polar-RP, 10 Â 250 mm; mobile phase: 45% MeCN : 55% aqueous 50 mM ammonium acetate; flow rate = 4 mL/min). The single peak corresponding to [ 18 F]FEOBV eluted between 30 and 40 min (Figure 9 ). That product fraction was collected, diluted into 40 mL of sterile water, and passed through a C-18 Sep-Pak which was then washed with 10 mL of sterile water. [ 18 F]FEOBV was then eluted with 0.5 mL of EtOH (USP for injection) and collected in the Tracerlab FX FN product vial. The Sep-Pak was washed with 9.5 mL of saline to bring the final formulation volume to 10 mL. The final drug product was dispensed into a septum sealed, sterile, pyrogen-free glass vial through a 0.22 mm sterile filter and submitted for QC testing as outlined in Quality Control Procedures section. Typical yields of [ 18 F]FEOBV using this method were 9.4% (nondecay corrected, n = 10).
Tracerlab production with SPE purification
Production of [ 18 F]sodium fluoride
Introduction: Globally, about 70 000 nuclear medicine diagnostic imaging procedures, including bone imaging, are performed using technetium-99m every day. 59 Technetium-99 m is obtained as the decay product from molybdenum-99, but despite this demand, only six nuclear reactors worldwide are capable of producing molybdenum-99. During 2009, the Chalk River nuclear reactor in Canada has been shutdown for unscheduled repairs leaving thousands of hospitals in North America without a supply of technetium-99m and a crisis in the molecular imaging community. 59, 60 Consequently, alternatives to technetium-99m scans are in high demand and [
18 F]sodium fluoride represents an easily accessible PET imaging alternative to technetium-99m bone imaging agents. 61, 62 In an effort to address the worldwide 13 in which a Tracerlab FX FN was reconfigured to allow full automation of the method for producing sodium fluoride reported by Nandy et al.. 63 The Tracerlab was configured as shown in Figure 10 and vials were loaded as follows: vial 7: 0.9% sodium chloride, USP for injection (10 mL); vial 9: sterile water for injection, USP (10 mL); dilution flask sterile water for injection, USP (10 mL). The delivery line from the cyclotron was connected to the dilution flask via plastic luer lock fittings which enable easy switching between delivery of fluoride to the target vial for a routine synthesis, and delivery to the dilution flask for preparation of [ 18 F]sodium fluoride. Furthermore, these fittings allow easy incorporation of Sep-Paks into the target delivery line.
A QMA-light Sep-Pak, preconditioned by flushing with ethanol (10 mL) followed by Sterile Water for Injection, USP (10 mL), was placed in the C18 cradle (between V15 and V17), a Plus-CM cation exchange cartridge was incorporated into the target delivery line and a sterile product vial with appropriate sterile filters was attached to the product delivery line. Note that since [ 18 F]sodium fluoride is prepared using the reformulation portion of the Tracerlab FX FN synthesis module, a feature that is common to other Tracerlab modules including the Tracerlab FX c-pro , this method can easily be transferred to other synthesis modules.
Fluoride-18 was delivered to the dilution flask through an inline Plus-CM cation exchange cartridge (to remove positively charged recoil nuclei generated concomitantly with fluoride-18 in the cyclotron target). Following completion of the cyclotron delivery, the solution of fluoride-18 was then transferred (Ar pressure) through the QMA-light Sep-Pak, trapping the fluoride-18 and passing the water to waste. Following trapping, the QMA-light Sep-Pak was then washed with an additional 10 mL of Sterile Water for Injection, USP to remove residual Introduction: Choline is a salt that is found in all cells where it is essential for the biosynthesis of phospholipids.
64 Such phospholipids are then incorporated into cell membranes and therefore radiolabeled analogs of choline can be used to monitor the rate of production of cell membranes in vivo, and thus rate of cell proliferation. Like As the demand for [ 18 F]fluorocholine from our PET center has increased heavily of late, we decided to adapt Kryza's method for use on a TracerLab FX FN , and herein report the first results from these research efforts.
Synthesis procedures: The TracerLab FX FN was configured as shown in Figure 11 and the reagent vials were loaded as follows: Vial 1: potassium carbonate (3.5 mg in 0.5 mL water); Vial 2: kryptofix-2.2.2 (15 mg in 1 mL MeCN); Vial 3: dibromomethane (300 mL in 0.7 mL MeCN); Vial 7: sterile water for injection, USP (15 mL); Vial 8: 0.9% sodium chloride for injection, USP (3.0 mL); Vial 9: ethanol (10.0 mL); C-18 Sep-Pak light: precharged with N,N-dimethylamino ethanol (1 mL).
The front end of the synthesis module was configured as for a typical radiofluorination reaction. The line from the reactor needle out through V14 (normally connected to an alumina cartridge as shown in Figures 3 and 4 ) was connected to 3 Â silica Sep-Pak cartridges connected in series. The third silica cartridge was then connected (by luer fitting) to V17. N,N-Dimethylamino ethanol (400 mL) was loaded onto a C18 Sep-Pak and then this was stacked on top of a CM-plus Sep-Pak in the Tracerlab FX FN C18 cradle.
Following drying of the fluoride using the general procedure, dibromomethane precursor was added to the reactor and the reaction was heated to 951C for 5 min. After this time, the reactor was cooled (401C), and the [ 18 F]fluoromethylcholine is positively charged it was trapped on the CM-Plus cation exchange resin, while the uncharged precursor species were washed to waste. The CM was then washed with Sterile Water for Injection, USP to remove any residual solvents and by-products. Finally, [ 18 F]fluoromethylcholine was eluted from the CM-Plus Sep-Pak into the collection flask with sterile saline (3 mL). The dose was passed through a sterile filter into a sterile dose vial and released for quality control testing (Quality Control Procedures section). Typical nondecay corrected yields of [ 18 F]fluoromethylcholine using this optimized production method were 5%, (n = 7). Doses were free of residual solvents, kryptofix-2.2.2 and dibromomethane, but were found to contain residual DMAE (100-000 mg/mL). The radiochemical yield of fluorocholine, and levels of residual DMAE, were similar to that reported by Kryza et al., 15 and proved acceptable for our current preclinical demands. Nevertheless, optimization of this chemistry, particularly exploiting recent improvements reported by Slaets et al., 18 F]SFB was not trivial and required a three-step radiochemical synthesis which used multiple reaction vessels. Typically this is done manually, 71 but the process has also been automated, 16, 72 although successful automation does require access to synthesis modules possessing multiple reaction vessels. A breakthrough came when Kabalka and co-workers reported a one-pot synthesis of [ 18 F]SFB requiring only Sep-Pak purification. 73 We recently reported a fully automated synthesis of [ 18 Figure 12 and vials were loaded as follows: Vial 1: potassium carbonate (3.5 mg in 0.5 mL water); Vial 2: kryptofix-2.2.2 (15 mg in 1 mL MeCN); Vial 3: 4-(ethoxycarbonyl)-N,N,N-trimethylbenzenaminium triflate precursor (5 mg in 0.5 mL DMSO); Vial 4: TPAH (20 mL in 0.5 mL MeCN); Vial 5: acetonitrile (1 mL); Vial 6: TSTU (10 mg in 0.6 mL MeCN); Vial 7: MeCN (2 mL); Vial 9: 10% MeCN in water (10 mL); dilution flask: 5 mL of 5% acetic acid and 15 mL water.
Following drying of the fluoride using the general procedure, the trimethylbenzeneaminium triflate precursor (5 mg in 0.5 mL DMSO) was added to the reactor and the reaction vessel was heated to 901C for 10 min to provide [
18 F]ethyl 4-fluorobenzoate. After this time, tetrapropylammonium hydroxide (TPAH, 20 mL in 0.5 mL MeCN) was added to saponify the ester group. Heating at 1201C for 3 min provides [
18 F]4-fluorobenzoic acid as the corresponding TPA salt. After saponification, O-(N-succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TSTU, 10 mg in 0.6 mL MeCN) was added and the reaction vessel was heated at 901C for 5 min to provide [
18 F]SFB. The crude reaction mixture was then cooled down (401C) and transferred to the round-bottomed dilution flask (precharged with 10 mL of 1.5% acetic acid) and the resulting solution was transferred through a Waters C18 Plus Sep-Pak. The C18 Sep-Pak was then washed with 10% MeCN (10 mL) to elute off unwanted hydrophilic impurities including unreacted fluoride-18. Following washing, [ 18 F]SFB was eluted off into the collection vial with neat MeCN (2 mL). Typical yields of [ 18 F]SFB using this method were 38% (nondecay corrected, n = 20) and radiochemical purity 
Synthesis module cleaning
The radiopharmaceuticals described in the earlier sections can be prepared on a single Tracerlab FX FN . Changing between module configurations is straightforward if the luer-lock fittings described in Introduction section are incorporated into the Tracerlab. However, module reconfiguration does raise the issue of how best to clean and dry the module between syntheses, especially syntheses using different module setups. In order to accomplish this reliably, the Tracerlab is returned to its basic configuration (Figure 3) , after completion of a given synthesis, and then Clean, Clean-Disinfect, and Dry cycles are performed as outlined below. Note that the round-bottomed dilution flask and product collection vial are removed, washed and oven-dried separately between syntheses and after completion of the cleaning cycles. The reaction vessel should be checked afterwards to ensure cleanliness and can also be further cleaned and oven-dried manually if required. It is recommended that the reactor be cleaned in this fashion at least once a week.
Clean cycle
Vials 1, 4, 5, 6, 7 and 9 are charged with sterile water. The water from vials 1, 4, 5 and 6 is washed into the reactor and then out, through the HPLC load loop, to waste. Similarly, the water from vials 7 and 9 is washed through the lines connecting the vials to V-17 and subsequently to waste. This ensures that the main lines of the synthesis module all get washed with sterile water.
Clean-disinfect cycle Vials 1-6 are charged with 70% ethanol in sterile water. The 70% ethanol from all of the vials is washed into the reactor and then out, through the HPLC load loop, to waste. Moreover, 70% ethanol is pumped through the HPLC column and associated lines. During this cycle, the product collection vial is also washed with 70% ethanol to disinfect it. These steps ensure that the main lines of the synthesis module are sterilized during the clean and disinfect cycle, and that the HPLC column is stored under 70% ethanol between runs.
Dry cycle
Vials 1-6 are charged with acetone. The acetone from all of the vials is washed into the reactor and the reactor is then heated to 801C for 5 min. After this time, the reactor is cooled and the acetone is pushed out, through the HPLC load loop, to waste. Subsequently, all of the vials and lines are dried with both argon pressure and vacuum over 20 min, to ensure that all water and acetone are removed from the synthesis module. 
Quality control procedures
Visual inspection
Doses are visually examined and must be clear, colorless and free of particulate matter.
Dose pH
The pH of the doses is analyzed by applying a small amount of the dose to colorpHast s pH 2.0-9.0 nonbleeding pH-indicator strips and determined by visual comparison to the scale provided.
Chemical purity and radiochemical purity/identity
Chemical and radiochemical purity/identity are analyzed using a Shimadzu VP-Series HPLC equipped with a Bioscan FC3300 radioactivity detector and either a conductivity detector ( 
Radionuclidic identity
Radionuclidic identity is confirmed by measuring the half-life of radiopharmaceutical doses and comparing it to the known halflife of fluorine-18 (109.77 min). Activities are measured using a Capintec CRC s -15R Radioisotope Dose Calibrator and half-life is calculated using Equation (1). Calculated half-life must be 105-115 min. 
Radionuclidic purity
Radionuclidic purity is analyzed by gamma-ray spectrometry and doses from the University of Michigan are allowed to decay, and then sent out to a CRO (Dade Moeller and Associates, Gaithersburg, MD) to test for the presence of long-lived radioactive contaminants.
Sterile filter integrity test
Sterile filters from doses (with needle still attached) are connected to a nitrogen supply via a regulator. The needle is then submerged in water and the nitrogen pressure gradually increased. If the pressure is raised above the filter acceptance pressure (typically 50 psi) without seeing a stream of bubbles, the filter is considered intact.
Bacterial endotoxins
Endotoxin content in radiopharmaceutical doses is analyzed by a Charles River Laboratories EndoSafe s Portable Testing System and according to the US Pharmacopeia. Doses must contain o175 EU. e For the preclinical work described in this study, no efforts were made to optimize specific activity of [ ]-labeled radiopharmaceutical doses and incubated (along with positive and negative controls) for 14 days. FTM is used to test for anaerobes, aerobes and microaerophiles while SCDM is used to test for nonfastidious and fastidious microorganisms. Culture tubes are visually inspected on the 3rd, 8th and 14th days of the test period and compared with the positive and negative standards. Positive standards must show growth (turbidity) on the plates and dose/negative controls must have no culture growth after 14 days to be indicative of sterility (Table 1) .
Conclusions
In conclusion, the Tracerlab FX FN has proven a versatile and efficient automated synthesis module in our hands. The results disclosed herein demonstrate that through simple incorporation of luer lock fittings, the synthesis module can be configured (and re-configured) in a straightforward manner to allow production of clinical doses of many different radiopharmaceuticals. As proof-of-concept, the production of each radiopharmaceutical discussed in this paper uses a different state-ofthe-art radiochemical technique. Each synthesis has been fully automated and all radiopharmaceutical doses for clinical use meet and exceed established quality control criteria.
